What Is Targeted Therapy for Breast Cancer?

Targeted therapy uses medication designed to interfere with a molecule, protein, receptor, enzyme, or signaling pathway that helps cancer cells grow and survive. Some drugs attach to targets on the cell surface. Others enter the cell and block internal growth signals. Antibody-drug conjugates go a step further by using an antibody to deliver a cancer-killing payload to cells carrying a particular target.

This differs from conventional chemotherapy, which primarily attacks rapidly dividing cells. Chemotherapy can damage cancer cells effectively, but it may also affect healthy fast-growing cells in the hair follicles, digestive tract, and bone marrow. Targeted drugs may avoid some of those effects, yet they can create their own problems, including diarrhea, low blood counts, heart changes, liver inflammation, high blood sugar, skin reactions, or lung injury.

Targeted therapy may be given before surgery, after surgery, or for cancer that is locally advanced, recurrent, or metastatic. It can be used alone, but it is often combined with endocrine therapy, chemotherapy, immunotherapy, or another targeted drug.

Evidence basis: NCI and American Cancer Society explanations of targeted treatment.

Biomarker Testing: Building the Tumor’s Molecular Profile

A targeted drug is useful only when its target is present or when clinical evidence shows that a particular tumor type is likely to respond. That is why biomarker testing has become central to breast cancer care.

Hormone receptor and HER2 testing

Nearly every invasive breast cancer is tested for estrogen receptors, progesterone receptors, and HER2. These results create familiar categories such as hormone receptor-positive, HER2-positive, HER2-negative, and triple-negative breast cancer.

HER2 testing is becoming more nuanced. A tumor may be traditionally HER2-positive, HER2-low, HER2-ultralow, or HER2-zero based on the amount and pattern of protein detected. These distinctions matter because some antibody-drug conjugates can benefit cancers that do not meet the traditional definition of HER2-positive disease.

Inherited and tumor-specific genetic testing

Germline testing looks for inherited variants, including harmful changes in BRCA1 and BRCA2. Tumor profiling examines changes acquired by the cancer itself. Depending on the diagnosis and treatment setting, testing may evaluate genes such as PIK3CA, AKT1, PTEN, and ESR1.

Testing may use tissue from the original biopsy, a later metastatic biopsy, or circulating tumor DNA collected through a blood test. A repeat test can sometimes uncover a new treatment target because cancer evolves under treatment pressure. Tumors, unfortunately, are very committed to professional development.

Evidence basis: FDA biomarker-linked approvals and NCI information on targetable pathways.

HER2-Targeted Therapies

HER2-positive breast cancer produces excessive HER2 protein or carries extra copies of the HER2 gene. Before HER2-directed drugs became available, this subtype was associated with aggressive behavior. It is still serious, but it now has one of the deepest targeted-treatment toolboxes in oncology.

Monoclonal antibodies

Trastuzumab attaches to the HER2 receptor and disrupts signals that promote tumor growth. It may also help the immune system recognize cancer cells. Depending on the stage and treatment plan, trastuzumab can be paired with chemotherapy, endocrine therapy, pertuzumab, or other drugs.

Pertuzumab binds to a different region of HER2. Using trastuzumab and pertuzumab together creates a broader blockade, rather like putting two locks on the same biologically troublesome door.

Because HER2-targeted antibodies can affect heart function, clinicians may order echocardiograms or other cardiac tests before and during treatment. A change in heart function does not occur in everyone, but monitoring helps the care team identify trouble early.

Antibody-drug conjugates

Antibody-drug conjugates, commonly called ADCs, combine a targeting antibody with a potent cancer-killing drug. The antibody recognizes a protein on the cancer cell, carries the payload toward it, and releases the medicine after the complex is taken into the cell or reaches the surrounding tumor environment.

Ado-trastuzumab emtansine, also known as T-DM1, is used in selected HER2-positive settings, including certain patients with residual invasive disease after treatment given before surgery.

Fam-trastuzumab deruxtecan, or T-DXd, has expanded the reach of HER2-directed treatment. Its uses now include several HER2-positive settings as well as eligible HER2-low and HER2-ultralow metastatic cancers. In December 2025, the FDA approved T-DXd with pertuzumab as a first-line option for certain unresectable or metastatic HER2-positive cancers. In May 2026, the agency added two early-stage HER2-positive indications.

T-DXd can produce significant tumor responses, but it carries a serious risk of interstitial lung disease and pneumonitis. A new or worsening cough, shortness of breath, fever, or unexplained breathing change should be reported promptly rather than saved for the next routine appointment.

HER2-directed kinase inhibitors

Small-molecule drugs such as tucatinib, neratinib, and lapatinib block signals generated by HER-family proteins from inside the cell. Tucatinib-containing combinations can be especially relevant in advanced HER2-positive disease, including for some people with brain metastases.

Treatment choices continue to evolve. In June 2026, the FDA approved palbociclib with trastuzumab, with or without pertuzumab, plus endocrine therapy as maintenance treatment for eligible hormone receptor-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment.

Evidence basis: Komen HER2 resources and current FDA approvals.

Targeted Treatment for HR-Positive, HER2-Negative Breast Cancer

Hormone receptor-positive, HER2-negative disease is the most common broad breast cancer subtype. Endocrine therapy remains a foundation of treatment, but targeted drugs can strengthen its effects, delay resistance, or address a newly discovered mutation.

CDK4/6 inhibitors

CDK4 and CDK6 are enzymes that help cells move through the division cycle. Blocking them can put susceptible cancer cells into something resembling a prolonged biological time-out.

Abemaciclib, palbociclib, and ribociclib are commonly combined with endocrine therapy in metastatic HR-positive, HER2-negative breast cancer. Abemaciclib and ribociclib also have roles in selected patients with higher-risk early-stage disease.

Side effects vary by drug but may include low white blood cell counts, fatigue, diarrhea, nausea, liver-test abnormalities, blood clots, and changes in the heart’s electrical rhythm. Blood counts and laboratory testing are routine, not decorative paperwork invented by a bored oncology office.

PI3K, AKT, and mTOR pathway inhibitors

The PI3K-AKT-mTOR pathway functions like an internal growth-control network. Changes affecting this pathway can help breast cancer resist endocrine treatment.

Alpelisib may be combined with fulvestrant for eligible HR-positive, HER2-negative advanced breast cancers carrying a PIK3CA mutation. Inavolisib is another mutation-directed option used in a specific combination for endocrine-resistant, PIK3CA-mutated disease.

Capivasertib targets AKT and may be paired with fulvestrant for eligible advanced cancers with alterations involving PIK3CA, AKT1, or PTEN. Everolimus blocks mTOR and can help restore sensitivity to endocrine therapy in selected situations.

In July 2026, the FDA approved gedatolisib with fulvestrant, with or without palbociclib, for a defined group of patients with HR-positive, HER2-negative advanced breast cancer without a detected PIK3CA mutation after progression on endocrine therapy. The approval illustrates how treatment is being divided into increasingly specific molecular lanes.

Targeting ESR1-driven resistance

An ESR1 mutation can allow the estrogen receptor to remain active even when estrogen is scarce, reducing the effectiveness of some endocrine therapies. Oral estrogen-receptor-directed medicines can provide alternatives for eligible patients whose cancer carries this mutation.

Elacestrant, imlunestrant, and vepdegestrant are examples of therapies developed for defined ER-positive, HER2-negative, ESR1-mutated advanced breast cancer settings. Vepdegestrant is a protein degrader designed to pull the estrogen receptor into the cell’s disposal machinery rather than merely blocking it.

Evidence basis: Komen CDK4/6 information and FDA approvals for pathway- and ESR1-directed drugs.

PARP Inhibitors for BRCA-Associated Breast Cancer

BRCA1 and BRCA2 proteins help repair certain forms of DNA damage. When a cancer cell already lacks effective BRCA-related repair, blocking another repair enzyme called PARP can push the cell beyond its ability to survive. This strategy is often described as synthetic lethality: two repair problems that are far more destructive together than either one alone.

Olaparib and talazoparib are PARP inhibitors used for eligible HER2-negative metastatic breast cancers associated with inherited harmful BRCA1 or BRCA2 variants. Olaparib may also be used after local treatment and chemotherapy for selected patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Possible side effects include anemia, fatigue, nausea, appetite changes, and other reductions in blood counts. Rare but serious bone marrow disorders can occur, making ongoing laboratory monitoring important.

Evidence basis: Komen PARP guidance, American Cancer Society stage-specific treatment information, and FDA approval history.

Antibody-Drug Conjugates in Triple-Negative and HER2-Negative Disease

Triple-negative breast cancer lacks estrogen receptors, progesterone receptors, and traditional HER2 positivity, so it does not respond to many of the targets used in other subtypes. ADCs have helped change that picture.

Sacituzumab govitecan targets TROP2, a protein commonly found on breast cancer cells, and delivers a topoisomerase-inhibiting payload. Datopotamab deruxtecan is another TROP2-directed ADC used in specified advanced breast cancer settings.

In June 2026, the FDA approved sacituzumab govitecan as first-line treatment for certain adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone for patients who are not candidates for PD-1 or PD-L1 therapy or with pembrolizumab for eligible PD-L1-positive disease. The exact indication, biomarker requirements, and prior-treatment rules matter, so a drug name alone never tells the whole treatment story.

ADCs can cause low blood counts, nausea, diarrhea, fatigue, mouth irritation, hair loss, and other effects related to their payload. Their targeted delivery system does not mean that every molecule stays politely inside the tumor.

Evidence basis: NCI drug descriptions and current FDA ADC approvals.

How Doctors Choose a Targeted Therapy

Selecting treatment involves much more than matching one mutation to one medicine. An oncology team may consider:

• The cancer’s stage, location, and current symptoms
• Hormone receptor, HER2, and other biomarker results
• Whether a mutation is inherited or found only in the tumor
• Previous treatments and how long they controlled the disease
• Whether cancer involves the brain, liver, lungs, bones, or other organs
• Heart, liver, lung, bone marrow, and metabolic health
• Pregnancy plans, menopause status, and other medications
• Side-effect priorities, infusion access, insurance coverage, and daily routines

Treatment sequencing is especially important in metastatic breast cancer. The best first drug is not automatically the newest drug, and using every available therapy at once would create an impressive medication list but not necessarily a better outcome.

If cancer grows during treatment, clinicians may repeat imaging, biopsy a progressing tumor, or order circulating tumor DNA testing. The goal is to determine whether the original target remains present and whether a new vulnerability has emerged.

Side Effects and Safety Monitoring

The phrase “targeted therapy” can sound gentler than chemotherapy, but targeted does not mean harmless. Each drug class has a different safety profile, and combinations may produce overlapping effects.

Monitoring may include complete blood counts, liver and kidney tests, glucose checks, electrocardiograms, echocardiograms, and assessment for respiratory symptoms. Some medicines require dose breaks or reductions when side effects appear. A reduced dose is not a failed dose; it is often how treatment becomes sustainable.

Patients should contact their care team promptly for fever, breathing trouble, chest pain, severe or persistent diarrhea, uncontrolled vomiting, confusion, unusual bleeding, yellowing of the skin, signs of dehydration, or symptoms of a serious allergic reaction. The oncology team should provide drug-specific instructions because the urgent warning signs are not identical for every medicine.

Resistance, Clinical Trials, and the Future of Precision Treatment

Targeted therapy can control cancer for months or years, but resistance may eventually develop. A cancer cell can alter the target, activate a backup pathway, increase drug export, repair treatment-related damage, or simply allow a resistant subpopulation to take over.

Researchers are responding with new drug combinations, next-generation ADCs, protein degraders, bispecific antibodies, improved brain-penetrating agents, and blood tests that may identify molecular progression before it appears on a scan. Clinical trials are also exploring whether treatment can be adapted earlier when circulating tumor DNA reveals a resistance mutation.

A trial may offer access to a promising therapy, but “experimental” does not mean guaranteed to be better. Patients should ask about the trial phase, known risks, extra visits, randomization, costs, and what standard treatment would remain available outside the study.

Questions to Ask the Oncology Team

• What are my ER, PR, and HER2 results?
• Does my tumor qualify as HER2-low or HER2-ultralow?
• Should I have germline genetic testing or broader tumor profiling?
• Which biomarker makes me eligible for this treatment?
• What is the goal: cure, reducing recurrence risk, shrinking the cancer, or controlling it?
• How will we know whether the treatment is working?
• Which side effects require an urgent call?
• Could a dose adjustment preserve benefit while improving tolerability?
• Should my tumor or circulating DNA be tested again if the cancer progresses?

Conclusion

Targeted therapies have changed breast cancer from a disease treated mainly according to stage into a collection of biologically distinct conditions. HER2 status, hormone receptors, inherited BRCA variants, and tumor alterations involving pathways such as PI3K, AKT, PTEN, and ESR1 can all influence treatment.

These medicines are not microscopic magic arrows. They require accurate testing, careful sequencing, safety monitoring, and realistic discussions about benefits and risks. Even so, they have created options that would have sounded ambitious only a generation ago, including treatments for HER2-low tumors, mutation-driven endocrine resistance, BRCA-associated disease, and triple-negative breast cancer.

Because approvals and treatment guidelines change quickly, decisions should be based on current test results and a personalized discussion with a qualified oncology team.

What the Targeted-Therapy Experience Can Feel Like

The lived experience of targeted therapy often starts with a vocabulary avalanche. A patient may enter an appointment expecting to discuss “breast cancer” and leave carrying terms such as HER2, FISH, germline BRCA, PIK3CA, ESR1, CDK4/6, and antibody-drug conjugate. It can feel as though someone replaced a frightening diagnosis with a frightening diagnosis plus a graduate-level biology quiz.

Waiting for biomarker results can be one of the hardest stages. The laboratory work is not merely administrative; it may determine which treatments are available. Still, knowing that does not make the waiting easier. Many people describe wanting treatment to begin immediately while also understanding that a carefully chosen plan may be more valuable than the fastest possible plan.

Once therapy starts, the daily experience depends heavily on the drug. An infusion-based treatment can divide life into cycles: treatment day, recovery days, the week when energy begins to return, and then another visit appearing on the calendar with suspicious enthusiasm. Oral therapy may seem easier because it can be taken at home, but pills create different responsibilities. Patients may need to track doses, food instructions, drug interactions, laboratory appointments, and refill schedules.

The word “targeted” can also create unrealistic expectations. Family members may assume that a precision drug causes few side effects because it is aimed at cancer cells. Patients can then feel surprised or even guilty when fatigue, diarrhea, nausea, mouth sores, low blood counts, skin problems, or mental fog interfere with ordinary life. A more accurate expectation is that side effects may be different from those of conventional chemotherapy, not necessarily trivial.

Regular monitoring becomes part of the routine. Blood draws, heart scans, electrocardiograms, glucose tests, and symptom checklists may feel repetitive, but they help clinicians keep treatment within a safer range. Many people find it useful to keep a simple symptom diary containing the date, medication dose, bowel changes, temperature, pain, appetite, breathing symptoms, and questions for the next visit. This is not glamorous, but neither is trying to remember three weeks of digestive history while sitting under fluorescent clinic lighting.

Dose reductions and treatment breaks can be emotionally complicated. A patient may worry that taking less medication means giving the cancer an advantage. In reality, oncology dosing is often adjusted to balance effectiveness with tolerability. A treatment that can be continued safely may be more useful than a theoretically perfect dose that repeatedly causes severe toxicity.

Scans create another rhythm. The days before imaging may bring “scanxiety,” followed by relief, disappointment, or a mixed result that requires interpretation. Targeted therapy does not always make every tumor disappear. Stable disease, slower growth, or improvement in a dangerous organ can still represent meaningful benefit.

Practical concerns matter too. Insurance authorization, infusion transportation, specialty-pharmacy deliveries, copay assistance, childcare, and time away from work can influence how manageable a plan feels. Asking for help from an oncology social worker or financial navigator is not an admission of defeat. It is closer to calling technical support when the medical system begins acting like a printer that refuses to acknowledge its own paper tray.

Over time, many patients develop expertise in their own treatment. They learn which symptoms are expected, which require an urgent call, what foods are tolerable after an infusion, and when to schedule important activities. The goal is not to become cheerful about cancer. It is to build enough knowledge, support, and flexibility that treatment occupies part of life without being allowed to impersonate the whole thing.